Loading…
Employees: 649
Size Sino Medical Sciences Technology (688108.SS) is a China Health Care company (Medical Specialties) with a market value of $868M, the 2586th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥13.84 on 6 Nov 2026.
Performance Over six months the shares fell 35.5%, against -5.4% for the median peer and -16.4% for the China market (cap-weighted) — lowest of 21 in its peer set.
Growth Revenue grew 22.0% over the last twelve months (peer median +8.1%); the operating margin is 19.2% (peer median 10.2%).
Valuation It trades at 69.2× forward earnings against a peer median of 18.9× (most expensive of 17).
Price implies For today's price to make sense, revenue must grow about 31% a year for seven years (Req g). Recent delivered growth is +10%, so the hurdle is +21 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 1.6 points above its cost of capital (14.1% WACC).
Next results Next results expected around 26 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥611M | CN¥519M | CN¥455M | CN¥341M | CN¥192M |
| Revenue growth | — | +14% | +33% | +78% | — |
| Gross profit | CN¥444M | CN¥281M | CN¥210M | CN¥142M | CN¥54.2M |
| EBITDA | n/a | CN¥142M | CN¥57.4M | CN¥12.9M | -CN¥135M |
| Net income | CN¥95.3M | CN¥47.3M | CN¥1.50M | -CN¥39.6M | -CN¥162M |
| Free cash flow | CN¥193M | CN¥116M | CN¥61.3M | -CN¥10.5M | -CN¥221M |
| Capital expenditure | CN¥29.6M | CN¥45.8M | CN¥70.0M | CN¥67.7M | CN¥111M |
| Total debt | CN¥147M | CN¥130M | CN¥225M | CN¥199M | CN¥58.3M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 688108.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -10.4% | -3.3% | 4th lowest of 21 |
| 6-month return | -35.5% | -5.4% | lowest of 21 |
| Distance from 52-week high | -52.3% | -30.5% | 3rd lowest of 21 |
| Revenue growth (TTM) | +22.0% | +8.1% | 4th highest of 21 |
| Operating margin | 19.2% | 10.2% | 4th highest of 21 |
| Forward P/E | 69.2× | 18.9× | most expensive of 17 |
| Growth the price implies (Req g, 7 yrs) | 31.0% | 5.5% | 2nd most demanding of 16 |
| Growth delivered (Del g) | +9.9% | +12.1% | 6th lowest of 16 |
| Hurdle (Req g minus delivered) | +21.1 pp | -5.1 pp | 3rd most demanding of 16 |
| ROIC minus cost of capital | +1.6 pp | +1.5 pp | 11th highest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Sino Medical Sciences Technology 688108.SS | China | $868M | -35% | +22% | 19% | 69.2× | 31.0% | +9.9% |
| JINS 3046.T | Japan | $865M | -12% | +14% | 10% | 16.6× | -7.2% | +11.7% |
| MedCap MCAP.ST | Sweden | $864M | +6% | +17% | 15% | 26.4× | 2.9% | +20.9% |
| Modern Dental 3600.HK | Hong Kong | $871M | +19% | +12% | 22% | 8.8× | -7.0% | +11.3% |
| Menicon 7780.T | Japan | $854M | +12% | +5% | 9% | 19.3× | n/a | n/a |
| Beta Bionics BBNX | United States | $854M | +63% | +44% | -73% | n/a | n/a | n/a |
| Zylox-Tonbridge Medical Technology 2190.HK | Hong Kong | $851M | -13% | +39% | 25% | 15.9× | 5.5% | +105.8% |
| Cisen Pharmaceutical 603367.SS | China | $890M | -15% | -6% | 8% | 8.3× | -12.9% | -1.3% |
| Safilo SFL.MI | Italy | $890M | +24% | -4% | 9% | 16.0× | -0.5% | +4.7% |
| Bioventus BVS | United States | $894M | +1% | +4% | 10% | 13.1× | 6.9% | +12.1% |
| Beijing Aerospace Changfeng 600855.SS | China | $832M | -35% | -10% | -19% | n/a | n/a | n/a |
| OrthoPediatrics KIDS | United States | $829M | +78% | +16% | -8% | n/a | n/a | n/a |
| Mani 7730.T | Japan | $909M | -15% | +10% | 30% | 18.4× | 1.5% | +13.9% |
| Shanghai Runda Medical Technology 603108.SS | China | $909M | -25% | -12% | -2% | 25.1× | 22.2% | -0.2% |
| Beijing SDL Technology 002658.SZ | China | $910M | -21% | -13% | 9% | 23.6× | 18.0% | +2.9% |
| Hangzhou Biotest Biotech 688767.SS | China | $824M | +5% | -4% | 3% | 34.7× | n/a | n/a |
| Advanced Medical Solutions AMS.L | United Kingdom | $824M | +14% | +6% | 12% | 20.7× | 19.6% | +21.4% |
| LifeTech Scientific 1302.HK | Hong Kong | $914M | -18% | +1% | 12% | 23.5× | 13.3% | +15.5% |
| Ningbo Jansen Superconducting Technologies 688805.SS | China | $915M | -30% | +36% | 14% | n/a | 47.2% | +17.1% |
| Seegene 096530.KS | South Korea | $915M | +26% | +12% | 13% | 15.9× | -3.4% | -15.9% |
| Aidite (Qinhuangdao) Technology 301580.SZ | China | $919M | -20% | +17% | 18% | 27.1× | 19.9% | +23.3% |